Sponsored Links
BRIEF-Cardiovascular risk for Novo nordisk's degludec insulin uncertain: chair of FDA panel
Nov 8 (Reuters) - Novo Nordisk A/S : * FDA advisory panel acting chairperson says panel members generally agree that signal of cardiovascular risk was seen for Novo nordisk's
degludec insulin, and that it "may or may not be real" risk
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters